Belharra

TOLREMO Appoints Industry Veterans Jeff Jonker and Mike Sherman to Board of Directors

Retrieved on: 
Thursday, March 21, 2024
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, Boston Scientific, Werewolf, Growth, Genentech, Strategic management, CFO, Business, Novartis, Trustee, Patient, Chairperson, Tuck School of Business, CBO, Sale, Business development, Acquisition, University, IPO, Belharra, Columbia Law School, Doctor of Philosophy, Senior, MBA, Clinical trial, Therapy, Guidant, DePauw University, Claremont McKenna College, Drug resistance, Celgene, FDA, Economics, Corporation, Management

TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Jeff Jonker and Mike Sherman to its Board of Directors.

Key Points: 
  • TOLREMO therapeutics AG (TOLREMO) today announced the appointment of Jeff Jonker and Mike Sherman to its Board of Directors.
  • "We welcome Jeff and Mike to our Board of Directors as we make steady progress with TT125-802 in the clinic and continue our evolution into a clinical-stage company with expanding operations,” said Stefanie Flückiger-Mangual, PhD, Co-founder and Chief Executive Officer of TOLREMO.
  • Jeff Jonker is an accomplished biotechnology executive with a wealth of experience across various leadership roles in the industry.
  • Mike Sherman is a seasoned executive with over 30 years of life science experience and an established track record in biotech leadership.

GoCoach Relaunches as SkillCycle to Address Large Gap in HR Tech Landscape

Retrieved on: 
Tuesday, January 24, 2023
Interview, Ecosystem, Learning, Fortune 500, L&D, Growth, Belharra, Drug discovery, Organization, HR, Human Capital, ICF, Management, Tutoring

PHILADELPHIA, Jan. 24, 2023 /PRNewswire/ -- GoCoach, a leading Coach Marketplace and Learning Experience Platform that serves mid-market and enterprise customers, today announced a series of innovative product developments including a company rebrand as SkillCycle and a complete overhaul of its core user experience. SkillCycle now brings all of the tenets of talent, learning, and career development together into one ecosystem to weave personalized learning into every stage of the employee lifecycle to empower companies to develop human capital before its managed.

Key Points: 
  • "I spent 20 years in HR vetting systems built by non-HR people that were essentially designed backwards," said Kristy McCann Flynn, Co-founder and CEO of SkillCycle.
  • SkillCycle is redefining the Human Capital Development category with key offerings at a time when recruitment and retention challenges are rampant.
  • Skillcycle brings equity in development to enhance equity in jobs, pay and more with learning at its core.
  • To date, Skillcycle has hundreds of customers including Fortune 500 companies and nearly 400 ICF-certified skill coaches.

Belharra Therapeutics Announces Broad Collaboration with Genentech to Discover and Develop Novel Medicines Across Multiple Therapeutic Areas

Retrieved on: 
Wednesday, January 4, 2023
Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Oncology, Hoffmann-La Roche, Therapy, MD, Sale, Disease, Patient, Proteome, Roche, Autoimmunity, Doctor of Philosophy, Neurodegeneration, Pharmaceutical industry, Fine chemical, Belharra, Genentech

Belharra Therapeutics, a privately held drug discovery company with a novel photoaffinity-based, non-covalent chemoproteomics platform, today announced a multi-year collaboration with Genentech, a member of the Roche Group.

Key Points: 
  • Belharra Therapeutics, a privately held drug discovery company with a novel photoaffinity-based, non-covalent chemoproteomics platform, today announced a multi-year collaboration with Genentech, a member of the Roche Group.
  • The companies will collaborate employing Belharra’s proprietary platform to discover and develop small molecule medicines in multiple therapeutic areas including oncology, immuno-oncology, autoimmune, and neurodegenerative diseases.
  • The company’s proprietary screening library enables Belharra scientists to identify any binding site, on any protein, in any conformational state, in any cell type.
  • “Partnering with early-stage companies like Belharra provides Genentech with yet another way to advance groundbreaking science to discover and develop medicines for patients with serious and life-threatening diseases.”